Tysabri and PML: What the FDA Label Says About Risk

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Information to Targeted Legal Inquiry

If you or a loved one is taking Tysabri, you may have heard about the risk of progressive multifocal leukoencephalopathy (PML). This serious brain infection has been documented in patients treated with Tysabri, with cases reported in medical literature over the years. The FDA label carries specific warnings about PML risk factors and monitoring recommendations. This page reviews the reported patterns of Tysabri-associated PML as described in published studies and regulatory guidance.

Understanding Tysabri and Its Association with PML

Tysabri (natalizumab) is a biologic therapy approved for the treatment of multiple sclerosis and Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. The U.S. Food and Drug Administration (FDA) has issued a boxed warning for Tysabri, stating that the drug 'increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability' (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This warning underscores the gravity of the association and the need for careful patient monitoring. PML is caused by reactivation of the JC virus, which typically remains dormant in immunocompetent individuals. Tysabri works by blocking the alpha-4 integrin receptor on immune cells, preventing their migration into the central nervous system. This mechanism, while effective for reducing inflammation in multiple sclerosis, also impairs immune surveillance against JC virus in the brain.

Risk Factors and Clinical Presentation of PML

The FDA label identifies three key risk factors for PML in Tysabri-treated patients: 'the presence of anti-JCV antibodies, duration of therapy, and prior use of immunosuppressants' (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who test positive for anti-JCV antibodies have a higher risk, and the risk increases with longer treatment duration, especially beyond two years. Prior use of immunosuppressive medications further elevates the risk. Clinical presentation of PML can be subtle and may include progressive neurological deficits such as weakness, gait disturbance, cognitive decline, and visual changes. The FDA label advises healthcare professionals to 'monitor patients on TYSABRI for any new sign or symptom that may be suggestive of PML' and to 'withhold TYSABRI immediately at the first sign or symptom suggestive of PML' (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Diagnosis typically involves brain MRI and detection of JC virus DNA in cerebrospinal fluid. Early recognition is critical because PML often leads to severe disability or death.

Adverse Event Data and Legal Implications

Adverse event data from the FDA Adverse Event Reporting System (FAERS) show that Tysabri is associated with a wide range of reported symptoms, including fatigue, multiple sclerosis relapse, headache, gait disturbance, and balance disorder (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While these reports do not directly confirm PML, they highlight the neurological and systemic burden experienced by patients. In clinical trials, PML occurred in three patients: two among 1869 multiple sclerosis patients treated for a median of 120 weeks, and one among 1043 Crohn's disease patients after eight doses (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These cases illustrate that PML can occur even with relatively short exposure. The adequacy of warnings regarding Tysabri and PML is a central concern. The FDA boxed warning is prominent, and the drug is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This program requires prescribers, patients, and pharmacies to enroll and adhere to monitoring protocols. However, questions may arise about whether patients were fully informed of the PML risk before starting treatment, especially regarding the significance of anti-JCV antibody testing and the cumulative risk over time.

Legal Considerations for Ohio Patients

For patients who develop PML, the timeline between exposure and documented harm can vary. The FDA label notes that risk increases with longer treatment duration, but PML has been reported after as few as eight doses (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This variability underscores the need for ongoing vigilance. For affected patients and their families, attorney-related considerations may include evaluating whether the prescribing physician adequately discussed PML risks, whether anti-JCV antibody testing was performed, and whether monitoring for neurological symptoms was conducted as recommended. Legal claims might focus on failure to warn, inadequate monitoring, or delayed diagnosis. The severity of PML—often leading to death or severe disability—makes timely legal action important. Patients who develop PML after Tysabri treatment may seek compensation for medical expenses, lost income, and pain and suffering. In summary, the evidence clearly establishes that Tysabri increases the risk of PML, a devastating brain infection. The FDA has mandated strong warnings and a restricted distribution program, but the risk remains significant, particularly for patients with anti-JCV antibodies, longer treatment duration, or prior immunosuppressant use. Patients and healthcare providers must remain alert to early signs of PML, and those affected should consider consulting with legal professionals experienced in pharmaceutical injury cases.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Tysabri and how is it linked to PML?

Tysabri (natalizumab) is a biologic therapy for multiple sclerosis and Crohn's disease. It increases the risk of progressive multifocal leukoencephalopathy (PML), a severe brain infection caused by the JC virus. The FDA has issued a boxed warning about this risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What are the main risk factors for developing PML while on Tysabri?

The three key risk factors are the presence of anti-JCV antibodies, longer duration of therapy (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What legal options do Ohio patients have if they developed PML after Tysabri?

Ohio patients who developed PML after Tysabri may pursue legal claims for failure to warn, inadequate monitoring, or delayed diagnosis. They may seek compensation for medical expenses, lost income, and pain and suffering. Consulting an attorney experienced in pharmaceutical injury cases is recommended.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.